PP_1170x120_10-25-21

Silarx Pharmaceuticals

Lannett cleared to market Xyzal Oral Solution generic

Lannett cleared to market Xyzal Oral Solution generic

PHILADELPHIA — Lannett Co. has gained Food and Drug Administration approval for levocetirizine dihydrochloride oral solution, 2.5 mg/5 ml (0.5 mg/ml), an allergy medication. Lannett said its product is a generic version of Xyzal Oral Solution 2.5 mg/5 ml (0.5 mg/ml) from UCB Inc. Plans call for levocetirizine dihydrochloride oral solution to be manufactured in

Lannett wraps up Silarx acquisition

Lannett wraps up Silarx acquisition

PHILADELPHIA — Lannett Co. has completed its acquisition of Silarx Pharmaceuticals Inc, , a manufacturer and marketer of liquid generic drug products. The deal also includes a related real estate entity, Lannett said Tuesday. When it announced the agreement in mid-May, Lannett said that it would retain Silarx’s entire senior management team, and there would be no

Lannett to purchase Silarx Pharmaceuticals

PHILADELPHIA — Lannett Co. plans to acquire Silarx Pharmaceuticals Inc., a manufacturer and marketer of liquid generic drug products. Financial terms of the agreement, which includes a related real estate entity, weren’t disclosed. Lannett said Monday that the boards of directors of both companies have unanimously approved the transaction, which is expected to be completed in early June, pending customary closing conditions. Co-founded